Comparison of Longitudinal Membrane Function in Peritoneal Dialysis Patients According to Dialysis Fluid Biocompatibility

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2020 Dec 11

PMID 33305111

Citations 3

Authors

A T N van Diepen

A M Coester

C J Janmaat

F W Dekker

D G Struijk

R T Krediet

Affiliations

Soon will be listed here.

Abstract

Introduction: Preservation of peritoneal function is essential in long-term peritoneal dialysis. Biocompatible dialysis solutions might prevent or postpone the membrane alteration resulting in ultrafiltration failure and consecutive morbidity and mortality.

Methods: We conducted an observational cohort study in which we made a longitudinal comparison between the course of peritoneal solute and fluid transport during treatment with conventional and biocompatible solutions. Therefore, prospectively collected peritoneal transport data from the yearly standard peritoneal permeability analysis were analyzed in 251 incident patients treated between 1994 and censoring in 2016. Fluid transport included small pore and free water transport. Solute transport was assessed by creatinine mass transfer area coefficient and glucose absorption. Linear mixed models including change point analyses were performed. Interaction with peritonitis was examined.

Results: One hundred thirty-five patients received conventional and 116 biocompatible solutions. Sixty-seven percent (conventional) and 64% (biocompatible) of these underwent minimally three transport measurements. Initially, biocompatible fluids showed higher small solute transport and lower ultrafiltration than conventional fluids up to 3 years. Thereafter, conventional fluids showed an increase in small solute transport (+2.7 ml/min per year; 95% confidence interval [CI]: 0.9 to 4.5) and a decrease of free water transport (-28.0 ml/min per year; 95% CI: -60.4 to 4.4). These were minor or absent in biocompatible treatment. Peritonitis induced a decrease of transcapillary ultrafiltration after 2 years on dialysis with conventional solutions (-291 ml/min per year; 95% CI: -550 to -32) while this was absent in biocompatible treatment.

Conclusion: Despite a higher initial solute transport with biocompatible solutions, these have less influence on functional long-term peritoneal alterations than conventional solutions.

Citing Articles

Aging of the Peritoneal Dialysis Membrane.

Krediet R Front Physiol. 2022; 13:885802.

PMID: 35574465 PMC: 9096116. DOI: 10.3389/fphys.2022.885802.

How peritoneal dialysis transforms the peritoneum and vasculature in children with chronic kidney disease-what can we learn for future treatment?.

Bartosova M, Zarogiannis S, Peter Schmitt C Mol Cell Pediatr. 2022; 9(1):9.

PMID: 35513740 PMC: 9072612. DOI: 10.1186/s40348-022-00141-3.

Survival of Peritoneal Membrane Function on Biocompatible Dialysis Solutions in a Peritoneal Dialysis Cohort Assessed by a Novel Test.

Balafa O, Duni A, Tseke P, Rapsomanikis K, Pavlakou P, Ikonomou M J Clin Med. 2021; 10(16).

PMID: 34441945 PMC: 8396924. DOI: 10.3390/jcm10163650.

References

Yu Z, Lambie M, Davies S . Longitudinal study of small solute transport and peritoneal protein clearance in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2013; 9(2):326-34. PMC: 3913234. DOI: 10.2215/CJN.04420413. View

Krediet R, van Diepen A, Coester A, Struijk D . Peritoneal vasculopathy in the pathophysiology of long-term ultrafiltration failure: A hypothesis based on clinical observations . Clin Nephrol. 2018; 91(1):1-8. DOI: 10.5414/CN109596. View

Davies S . Assessment of comorbidity in peritoneal dialysis patients. Contrib Nephrol. 2003; (140):98-103. DOI: 10.1159/000071429. View

Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl G, Frei U . Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol. 2000; 11(4):729-739. DOI: 10.1681/ASN.V114729. View

Mateijsen M, van der Wal A, Hendriks P, Zweers M, Mulder J, Struijk D . Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 2000; 19(6):517-25. View

Smit W, Struijk D, Ho-Dac-Pannekeet M, Krediet R . Quantification of free water transport in peritoneal dialysis. Kidney Int. 2004; 66(2):849-54. DOI: 10.1111/j.1523-1755.2004.00815.x. View

Umenishi F, Schrier R . Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene. J Biol Chem. 2003; 278(18):15765-70. DOI: 10.1074/jbc.M209980200. View

Johnson D, Brown F, Clarke M, Boudville N, Elias T, Foo M . The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant. 2012; 27(12):4445-53. PMC: 3520083. DOI: 10.1093/ndt/gfs314. View

Morelle J, Sow A, Hautem N, Bouzin C, Crott R, Devuyst O . Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis. J Am Soc Nephrol. 2015; 26(10):2521-33. PMC: 4587704. DOI: 10.1681/ASN.2014090939. View

10.

Michels W, Verduijn M, Parikova A, Boeschoten E, Struijk D, Dekker F . Time course of peritoneal function in automated and continuous peritoneal dialysis. Perit Dial Int. 2012; 32(6):605-11. PMC: 3524901. DOI: 10.3747/pdi.2011.00166. View

11.

Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jorres A, Lage C . Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant. 2004; 19(4):917-24. DOI: 10.1093/ndt/gfh013. View

12.

Davies S, Phillips L, Naish P, Russell G . Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001; 12(5):1046-1051. DOI: 10.1681/ASN.V1251046. View

13.

Cnaan A, Laird N, Slasor P . Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med. 1997; 16(20):2349-80. DOI: 10.1002/(sici)1097-0258(19971030)16:20<2349::aid-sim667>3.0.co;2-e. View

14.

Kawanishi K, Honda K, Tsukada M, Oda H, Nitta K . Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int. 2012; 33(3):242-51. PMC: 3649892. DOI: 10.3747/pdi.2011.00270. View

15.

Smit W, Parikova A, Struijk D, Krediet R . The difference in causes of early and late ultrafiltration failure in peritoneal dialysis. Perit Dial Int. 2005; 25 Suppl 3:S41-5. View

16.

van Esch S, Zweers M, Jansen M, de Waart D, van Manen J, Krediet R . Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. Perit Dial Int. 2004; 24(6):554-61. View

17.

Elphick E, Teece L, Chess J, Do J, Kim Y, Lee H . Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport. Clin J Am Soc Nephrol. 2018; 13(10):1526-1533. PMC: 6218832. DOI: 10.2215/CJN.02380218. View

18.

Peso G, Jimenez-Heffernan J, Selgas R, Remon C, Ossorio M, Fernandez-Perpen A . Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies. Perit Dial Int. 2015; 36(2):129-34. PMC: 4803356. DOI: 10.3747/pdi.2014.00038. View

19.

van Esch S, Struijk D, Krediet R . The Natural Time Course of Membrane Alterations During Peritoneal Dialysis Is Partly Altered by Peritonitis. Perit Dial Int. 2015; 36(4):448-56. PMC: 4934441. DOI: 10.3747/pdi.2014.00215. View

20.

Krediet R, Struijk D, Koomen G, Arisz L . Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans. 1991; 37(4):662-7. View